c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

c-Fms Inhibitors

AZD7507

Cat. No.: HY-117244

AZD7507 is a potent and orally active **CSF-1R** inhibitor, with antitumor activity.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BPR1R024

Cat. No.: HY-132935

BPR1R024 is an orally active and selective **CSF1R** inhibitor (IC_{50} = 0.53 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-1

Cat. No.: HY-18791

c-Fms-IN-1 is a **FMS kinase** inhibitor with an IC_{50} of 0.0008 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-10

Cat. No.: HY-126297

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of **FMS** (Colony stimulating factor-1 receptor, CSF-1R) with IC_{50} of 2 nM. c-Fms-IN-10 has anti-tumor activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Fms-IN-2

Cat. No.: HY-18787

c-Fms-IN-2 is a **FMS kinase** inhibitor with an IC_{50} of 0.024 μM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-3

Cat. No.: HY-13075

c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

c-Fms-IN-6

Cat. No.: HY-111947

c-Fms-IN-6 is a potent inhibitor of **c-FMS**, with an IC_{50} of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC_{50} > 1 μM). Used in the research of autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-7

Cat. No.: HY-111948

c-Fms-IN-7 is a **cFMS** inhibitor extracted from patent WO2011079076A1, example159, has an IC_{50} of 18.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-8

Cat. No.: HY-119942

c-Fms-IN-8 (compound 4a) is a **colony stimulating factor-1 receptor (CSF-1R, c-FMS)** Type II inhibitor, with an IC_{50} of 9.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-9

Cat. No.: HY-128680

c-Fms-IN-9 is a **c-FMS** inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (**uFMS**) and **uKIT** with IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cFMS Receptor Inhibitor II

Cat. No.: HY-112451

cFMS Receptor Inhibitor II is a **CSF1R** kinase inhibitor. CSF-1 is a cytokine.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-1

Cat. No.: HY-101774

CSF1R-IN-1 is a **CSF1R** inhibitor with an with an IC_{50} of 0.5 nM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-3

Cat. No.: HY-139990

CSF1R-IN-3 (compound 21) is a potent and orally active **CSF-1R** inhibitor (IC_{50}=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSF1R-IN-4

Cat. No.: HY-144040

CSF1R-IN-4 is a potent inhibitor of **CSF1R**. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSF1R-IN-5

Cat. No.: HY-144041

CSF1R-IN-5 is a potent inhibitor of **CSF1R**. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Edicotinib

(JNJ-40346527; JNJ-527)

Cat. No.: HY-109086

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active **colony-stimulating factor-1 receptor (CSF-1R)** inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GENZ-882706

(RA03546849)

Cat. No.: HY-101526

GENZ-882706 is a potent colony stimulating factor-1 receptor (**CSF-1R**) Inhibitor extracted from patent WO 2017015267A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GENZ-882706(Raceme)

(GENZ-882706 racemate)

Cat. No.: HY-101526R

GENZ-882706(Raceme) is the racemate of GENZ-882706.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW2580

Cat. No.: HY-10917

GW2580 is an orally bioavailable and selective inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

GW2580-d6

Cat. No.: HY-10917S

GW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JTE-952

Cat. No.: HY-122906

JTE-952 is a potent, oral active and selective Type II inhibitor of **colony stimulating factor-1 receptor** (**CSF-1R or cFMS**, type III receptor tyrosine kinase), with IC_{50} values of 13 nM and 261 nM for CSF1R and TrkA , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with IC_{50}s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride))

Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pexidartinib

(PLX-3397)

Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib hydrochloride

(PLX-3397 hydrochloride) Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg, 1 g

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PLX5622

Cat. No.: HY-114153

PLX5622 is a highly selective brain penetrant and orally active **CSF1R** inhibitor (IC_{50}=0.016 μM; K_i=5.9 nM). PLX5622 allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PLX5622 hemifumarate

Cat. No.: HY-114153A

PLX5622 hemifumarate is a highly selective brain penetrant and orally active **CSF1R** inhibitor (IC_{50}=0.016 μM; K_i=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PLX647

Cat. No.: HY-13838

PLX647 is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC_{50}s=91 and 130 nM, respectively).



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, reapectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent **FGFR1-4** and **CSF1R** inhibitor with IC_{50}s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.



Purity: 99.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sotuletinib

(BLZ945) Cat. No.: HY-12768

Sotuletinib (BLZ945) is a potent, selective and brain-penetrant **CSF-1R (c-Fms)** inhibitor with an IC_{50} of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vimseltinib

(DCC-3014) Cat. No.: HY-136256

Vimseltinib (DCC-3014) is a **c-FMS** (**CSF-IR**) and **c-Kit** dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg